Compare Aurobindo Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs CIPLA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA CIPLA AUROBINDO PHARMA/
CIPLA
 
P/E (TTM) x 16.9 33.3 50.7% View Chart
P/BV x 3.5 3.4 100.8% View Chart
Dividend Yield % 0.3 0.5 64.8%  

Financials

 AUROBINDO PHARMA   CIPLA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
CIPLA
Mar-19
AUROBINDO PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs830678 122.4%   
Low Rs527484 108.9%   
Sales per share (Unadj.) Rs333.9198.2 168.4%  
Earnings per share (Unadj.) Rs40.418.5 217.9%  
Cash flow per share (Unadj.) Rs51.835.0 147.9%  
Dividends per share (Unadj.) Rs2.503.00 83.3%  
Dividend yield (eoy) %0.40.5 71.3%  
Book value per share (Unadj.) Rs237.1186.3 127.2%  
Shares outstanding (eoy) m585.91805.70 72.7%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.02.9 69.3%   
Avg P/E ratio x16.831.4 53.6%  
P/CF ratio (eoy) x13.116.6 79.0%  
Price / Book Value ratio x2.93.1 91.8%  
Dividend payout %6.216.2 38.3%   
Avg Mkt Cap Rs m397,569468,031 84.9%   
No. of employees `00017.922.6 78.9%   
Total wages/salary Rs m25,84928,565 90.5%   
Avg. sales/employee Rs Th10,956.97,053.1 155.3%   
Avg. wages/employee Rs Th1,447.71,261.5 114.8%   
Avg. net profit/employee Rs Th1,324.3659.1 200.9%   
INCOME DATA
Net Sales Rs m195,636159,710 122.5%  
Other income Rs m1,5534,766 32.6%   
Total revenues Rs m197,189164,475 119.9%   
Gross profit Rs m39,51930,973 127.6%  
Depreciation Rs m6,68013,263 50.4%   
Interest Rs m2,6261,684 155.9%   
Profit before tax Rs m31,76720,791 152.8%   
Minority Interest Rs m27-172 -15.7%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2695,695 127.6%   
Profit after tax Rs m23,64514,924 158.4%  
Gross profit margin %20.219.4 104.2%  
Effective tax rate %22.927.4 83.5%   
Net profit margin %12.19.3 129.3%  
BALANCE SHEET DATA
Current assets Rs m153,645124,266 123.6%   
Current liabilities Rs m120,42937,715 319.3%   
Net working cap to sales %17.054.2 31.3%  
Current ratio x1.33.3 38.7%  
Inventory Days Days13591 149.2%  
Debtors Days Days6495 67.1%  
Net fixed assets Rs m103,909105,190 98.8%   
Share capital Rs m5861,611 36.4%   
"Free" reserves Rs m138,322148,511 93.1%   
Net worth Rs m138,908150,123 92.5%   
Long term debt Rs m1,80038,301 4.7%   
Total assets Rs m264,544239,633 110.4%  
Interest coverage x13.113.3 98.1%   
Debt to equity ratio x00.3 5.1%  
Sales to assets ratio x0.70.7 111.0%   
Return on assets %9.96.9 143.3%  
Return on equity %17.09.9 171.2%  
Return on capital %23.811.8 201.4%  
Exports to sales %49.634.7 143.0%   
Imports to sales %18.80-   
Exports (fob) Rs m97,09155,419 175.2%   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31657,410 169.5%   
Fx outflow Rs m40,58919,041 213.2%   
Net fx Rs m56,72738,368 147.8%   
CASH FLOW
From Operations Rs m16,22016,911 95.9%  
From Investments Rs m-28,768-16,687 172.4%  
From Financial Activity Rs m19,191-3,487 -550.3%  
Net Cashflow Rs m6,656-3,451 -192.9%  

Share Holding

Indian Promoters % 54.1 16.0 338.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 8.0 12.2 65.2%  
FIIs % 27.7 23.7 116.9%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.2 26.2 38.9%  
Shareholders   69,601 161,166 43.2%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 143 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day today, tracking weak global cues as coronavirus cases continue to surge across the world.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

A Warning for Traders: Don't Get Addicted to Hopium(Fast Profits Daily)

Jun 30, 2020

If you are a trader, you must watch out for this dangerous addiction.

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jul 10, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - VENUS REMEDIES COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS